Drug Profile
Research programme: kidney disorder therapeutics - Brigham and Women's Hospital/Evotec SE/Harvard University
Alternative Names: Acute kidney disease therapeutics - Brigham and Women's Hospital/Evotec SE/Harvard University; Chronic kidney disease therapeutics - Brigham and Women's Hospital/Evotec SE/Harvard University; CureNephronLatest Information Update: 27 Sep 2019
Price :
$50
*
At a glance
- Originator Brigham and Womens Hospital; Evotec AG; Harvard University; University of Southern California
- Developer Brigham and Womens Hospital; Evotec SE; Harvard University
- Class
- Mechanism of Action Cell death inhibitors; Cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Kidney disorders